Comparable Uncontrolled Transaction Analysis
Legacy intellectual Property Royalty Rate
Prepared for Penterra Pharmaceuticals Corp. IRS Examination Defense, Tax Years 2017–2020
Prepared by:
Whitmore Valuation Group LLC 200 Ashbury Asset Advisors, Suite 700 Boston, MA 02109
Lead Economist: Dr. Helena Vasquez, Ph.D., Managing Director Supporting Economist: Dr. Rohan Chakrabarti, Ph.D., Senior Director
Prepared at the Direction of Counsel:
Calderwood & Harkness LLP 1735 Market Street, Suite 3100 Philadelphia, PA 19103 C&H Matter Number: 1018-00009-KV
November 2022
PRIVILEGED AND CONFIDENTIAL — Prepared at the Direction of Counsel Pursuant to Kovel Arrangement — Attorney-Client Privilege and Work Product Doctrine Apply. This report and the analyses, opinions, and conclusions contained herein have been prepared by Whitmore Valuation Group LLC at the direction of Calderwood & Harkness LLP, counsel to Penterra Pharmaceuticals Corp., for the purpose of assisting counsel in rendering legal advice in connection with the IRS examination of tax years 2017–2020. This report is protected from disclosure under the attorney-client privilege and the work-product doctrine. No waiver of any privilege is intended by the preparation of this report. Distribution of this report is limited to authorized personnel of Calderwood & Harkness LLP and Penterra Pharmaceuticals Corp. and may not be disclosed, reproduced, or distributed without the prior written consent of Calderwood & Harkness LLP.
Right-click to update Table of Contents
I. Executive Summary
This report presents a Comparable Uncontrolled Transaction ("CUT") analysis of the arm's-length royalty rate applicable to the intercompany license of legacy pharmaceutical intellectual property from Penterra Pharmaceuticals Corp. ("PPC" or the "Taxpayer") to Penterra Biopharma International DAC ("PBI"), PPC's indirect wholly owned subsidiary organized under Irish law. Whitmore Valuation Group LLC ("Whitmore" or "WVG") has been engaged by Calderwood & Harkness LLP ("C&H"), counsel to PPC, pursuant to a Kovel arrangement, to prepare this analysis in connection with the defense of PPC's transfer pricing methodology during the IRS examination of tax years 2017 through 2020.
The intercompany transaction at issue involves a license granted by PPC to PBI covering certain legacy pharmaceutical compounds—specifically, compounds that were approved for commercial sale or were in late-stage clinical development prior to the establishment of the qualified cost-sharing arrangement ("CSA") on July 1, 2012. The legacy IP license, which is separate from and supplementary to the CSA, grants PBI the exclusive right to commercialize these compounds in territories outside the Americas (defined as North America, Central America, South America, and the Caribbean) in exchange for a running royalty equal to 4.5% of net sales in the non-Americas territory.
The IRS, through its examination team designated as LB&I-NE-TP-2022-00641 and led by Revenue Agent Patricia Dunleavy, with economic support provided by IRS Economist Dr. Alan Washburne, has proposed increasing the royalty rate from 4.5% to 11.0% of net sales. The IRS asserts that PPC's royalty rate understates the arm's-length compensation attributable to the legacy intellectual property and therefore understates U.S.-source income. The proposed royalty adjustment totals $188,040,000 across the four tax years at issue, calculated as the incremental royalty that would have been due at the IRS's proposed 11.0% rate relative to PPC's reported 4.5% rate. This royalty adjustment forms part of a larger net proposed adjustment of $380.4 million encompassing CSA-related adjustments and correlative offsets.
To evaluate the arm's-length nature of PPC's 4.5% royalty rate, Whitmore has conducted a comprehensive CUT analysis in accordance with Internal Revenue Code ("IRC") § 482 and Treasury Regulation ("Treas. Reg.") § 1.482-4(c). Our analysis involved the systematic identification, screening, and evaluation of uncontrolled third-party pharmaceutical license agreements that are comparable to the PPC-PBI legacy IP license. Through a rigorous, multi-step screening process applied to publicly available pharmaceutical license agreement databases, SEC filings, and industry sources, we identified 14 comparable uncontrolled license agreements that satisfy the comparability standards set forth in Treas. Reg. § 1.482-4(c)(2).
Based on our analysis of these 14 comparable uncontrolled transactions, the arm's-length interquartile range ("IQR") of royalty rates is 3.1% to 6.8% of net sales, with a median of 4.4%. PPC's 4.5% royalty rate falls squarely within this arm's-length range and is closely aligned with the median. Under Treas. Reg. § 1.482-1(e), when the result of a controlled transaction falls within the arm's-length range determined from comparable uncontrolled transactions, no adjustment to the controlled transaction is warranted. Accordingly, no adjustment to PPC's 4.5% royalty rate is required under the arm's-length standard.
The IRS's proposed 11.0% royalty rate, by contrast, falls materially outside the interquartile range, exceeding the 75th percentile by 4.2 percentage points and the median by 6.6 percentage points. Our analysis of the IRS's comparables, to the extent they have been identified through the examination process, indicates that the IRS's proposed rate is based on license agreements that are not adequately comparable to the PPC-PBI legacy IP license under the comparability standards of Treas. Reg. § 1.482-4(c)(2). Specific deficiencies in the IRS's comparables include the inclusion of agreements involving dissimilar therapeutic areas, different product development stages, different geographic scopes, and transactions that bundled milestone payments with running royalties in a manner that inflated the effective royalty rate.
In addition to the CUT benchmarking analysis, this report provides a detailed functional analysis of PBI demonstrating that PBI performs significant functions related to the development, enhancement, maintenance, protection, and exploitation ("DEMPE") of the licensed intangible property in the non-Americas territories, bears substantial market and regulatory risk, and possesses meaningful economic substance. PBI's functional profile is comparable to or exceeds that of the licensees observed in the 14 comparable uncontrolled transactions, further supporting a royalty rate at or near the median of the arm's-length range.
This report also provides additional support for PPC's contemporaneous transfer pricing documentation, which was prepared by Crestfield & Associates LLP for each of the four tax years at issue, and supports PPC's reasonable-cause defense against potential transfer pricing penalties under IRC § 6662(e)(3)(B).
II. Scope and Engagement
II.A. Retention and Privilege Framework
Whitmore Valuation Group LLC was retained by Calderwood & Harkness LLP, counsel to Penterra Pharmaceuticals Corp., pursuant to a Kovel engagement letter executed on June 20, 2022 (Reference: 1018-00009-KV). Under the terms of this engagement, all work performed by Whitmore in connection with this analysis has been conducted at the direction of counsel for the purpose of assisting counsel in providing legal advice to PPC in connection with the IRS's examination of PPC's federal income tax returns for tax years 2017 through 2020.
The engagement is supervised on behalf of C&H by Leonard Cross, Responsible Partner, and Sylvia Hartwell, Billing Partner. All communications between Whitmore and PPC, and between Whitmore and C&H, have been made in furtherance of the attorney-client relationship and for the purpose of facilitating the rendition of legal advice.
This report, and the analyses, opinions, conclusions, and work product contained herein, are protected from disclosure under the attorney-client privilege and the work-product doctrine. The privilege belongs to PPC as the client, and no waiver of any applicable privilege is intended by the preparation, delivery, or internal distribution of this report. This report is to be disclosed only to authorized personnel of Calderwood & Harkness LLP and Penterra Pharmaceuticals Corp. and may not be provided to any other party, including the IRS, without the express prior written consent of Calderwood & Harkness LLP.
The lead economist responsible for this analysis is Dr. Helena Vasquez, Managing Director of Whitmore Valuation Group LLC. Dr. Vasquez holds a Ph.D. in Economics and has more than twenty years of experience in transfer pricing economics, pharmaceutical IP valuation, and IRS controversy support. The supporting economist is Dr. Rohan Chakrabarti, Senior Director, who specializes in benchmarking studies, CUT analysis, and quantitative methods in transfer pricing. The qualifications and experience of Dr. Vasquez and Dr. Chakrabarti are set forth in detail in Appendix A to this report.
II.B. Scope of Analysis
The scope of this engagement, as defined by the direction of counsel, encompasses the following objectives:
1. Evaluate the arm's-length nature of the 4.5% royalty rate. Determine whether the 4.5% royalty rate charged by PPC to PBI for the intercompany license of legacy pharmaceutical intellectual property satisfies the arm's-length standard under IRC § 482 and the implementing regulations thereunder.
2. Apply the CUT method as the best method. Apply the Comparable Uncontrolled Transaction method under Treas. Reg. § 1.482-4(c) as the best method for testing the arm's-length nature of the royalty rate, in accordance with the best method rule set forth in Treas. Reg. § 1.482-1(c).
3. Identify, screen, and analyze comparable uncontrolled transactions. Conduct a systematic search of publicly available pharmaceutical license agreement databases, SEC filings, and other industry sources to identify third-party license agreements that are comparable to the PPC-PBI legacy IP license, and apply appropriate comparability screening criteria consistent with Treas. Reg. § 1.482-4(c)(2).
4. Determine the arm's-length range. Calculate the arm's-length range of royalty rates from the identified comparable transactions and assess PPC's 4.5% royalty rate against that range.
5. Address the IRS's proposed 11.0% rate. Evaluate the IRS's proposed 11.0% royalty rate and identify the bases upon which the IRS's rate is not supported by properly comparable uncontrolled transactions and is inconsistent with the arm's-length standard.
6. Perform sensitivity and robustness analyses. Conduct sensitivity testing to assess the stability and reliability of the arm's-length range under various alternative approaches to comparable selection and analysis.
7. Provide functional analysis support. Assess PBI's functions, assets, and risks as they relate to the comparability analysis and the determination of the appropriate royalty rate.
II.C. Information Relied Upon
In preparing this report, Whitmore has reviewed, analyzed, and relied upon the following categories of information and documentation:
• The intercompany legacy IP license agreement between PPC and PBI, including all amendments and schedules thereto;
• PPC and PBI audited and unaudited financial statements for the tax years 2017, 2018, 2019, and 2020;
• Contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner) for each of the four tax years at issue;
• Product-level revenue data for legacy compounds by territory, including detailed breakdowns of net sales in the non-Americas territory;
• PBI's functional profile documentation, including organizational charts, personnel data, job descriptions, and summaries of functions performed;
• PBI employee data, reflecting growth from 52 employees at the time of PBI's establishment in 2012 to 185 employees by the end of 2020;
• Minutes of PBI board of directors meetings, comprising 42 meetings held in Dublin during the 2017–2020 period;
• Information relating to PBI's regulatory expenditures, totaling €47.2 million on a cumulative basis for the 2017–2020 period;
• Information relating to PBI's pricing decisions across 68 country markets;
• The qualified cost-sharing arrangement between PPC and PBI, as background context;
• Publicly available pharmaceutical license agreement databases, including the Fenmore Services Inc. database, the Tidewater Health IT database, and other publicly available sources;
• SEC filings, including Forms 8-K, 10-K, and 10-Q, disclosing terms of third-party pharmaceutical license agreements;
• Pharmaceutical industry publications and market data sources;
• The IRS's Notice of Proposed Adjustment ("NOPA") dated October 12, 2023, and the 30-Day Letter dated November 8, 2023;
• Information Document Request ("IDR") responses provided by PPC during the course of the examination; and
• Published academic and professional literature relating to pharmaceutical royalty rates and transfer pricing methodology.
A comprehensive list of all documents and data sources relied upon in preparing this report is set forth in Appendix B.
III. Factual Background
III.A. Penterra Pharmaceuticals Corp. — Overview
Penterra Pharmaceuticals Corp. ("PPC" or the "Taxpayer") is a Delaware corporation, publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA (Employer Identification Number: 22-3741856). PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550.
PPC operates in the specialty pharmaceutical and biotechnology industry, with a focus on the development, manufacture, and commercialization of innovative therapies in three primary therapeutic areas: oncology, immunology, and rare-disease therapeutics. PPC conducts its research and development activities principally from its Princeton Junction campus, which houses approximately 2,800 scientific and clinical personnel, and from satellite research facilities in Cambridge, Massachusetts and San Diego, California.
For fiscal year 2020, PPC reported consolidated global revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. PPC employed approximately 14,500 individuals worldwide as of the end of fiscal year 2020, including employees of its global subsidiaries and affiliated entities.
PPC's senior management team includes Catherine Falk, Chief Executive Officer; Rajesh Iyer, Chief Financial Officer; Deborah Staines, General Counsel; and Marcus Whitfield, Vice President, Global Tax. Mr. Whitfield oversees PPC's global transfer pricing function and has primary responsibility for the company's intercompany pricing policies, contemporaneous documentation, and IRS examination responses.
PPC's product portfolio encompasses approximately 22 marketed products and a clinical pipeline of 37 compounds in various stages of development. PPC's legacy product portfolio, which is the subject of the intercompany license at issue in this report, includes compounds that were approved for commercial sale or were in late-stage clinical development prior to July 1, 2012, the effective date of the qualified cost-sharing arrangement between PPC and PBI.
III.B. Penterra Biopharma International DAC — Overview
Penterra Biopharma International DAC ("PBI") is a designated activity company organized under the laws of Ireland, with its registered office located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI was incorporated on March 15, 2012, in connection with PPC's global corporate restructuring and the establishment of the qualified cost-sharing arrangement.
PBI is 100% owned by Penterra Holdings Luxembourg S.à r.l. ("PHL"), a société à responsabilité limitée organized under the laws of Luxembourg and registered at 14, rue Aldringen, L-1118 Luxembourg (RCS Number B 168452). PHL is, in turn, 100% owned by PPC. PHL is treated as a disregarded entity for United States federal income tax purposes pursuant to the check-the-box regulations under Treas. Reg. § 301.7701-3. Accordingly, PBI is treated as a direct subsidiary of PPC for U.S. federal income tax purposes.
PBI functions as an IP-holding company and as the principal entity responsible for the commercialization of PPC's pharmaceutical products in territories outside the Americas. In this capacity, PBI manages contract manufacturing relationships, oversees regulatory filings and approvals in non-Americas markets, sets pricing strategies, selects and manages distribution partners, conducts medical affairs activities, and makes independent commercial decisions across an extensive geographic footprint encompassing the Europe, Middle East and Africa ("EMEA") and Asia-Pacific ("APAC") regions.
For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI employed 185 individuals as of the end of fiscal year 2020, a substantial increase from the 52 employees present at the time of PBI's establishment in 2012. PBI's managing director is Aidan Naughton, who has served in that role since PBI's incorporation and reports directly to PBI's board of directors.
PBI maintains a dedicated office of approximately 18,000 square feet at Sandyford Business Park in Dublin, housing its commercial, regulatory, finance, legal, and medical affairs functions. PBI's board of directors convened 42 meetings during the 2017–2020 period, all of which were held in Dublin. The board exercised independent oversight of PBI's commercial operations, pricing decisions, and strategic direction. PBI made independent pricing decisions across 68 country markets during the period at issue and incurred cumulative regulatory expenditures of €47.2 million over the 2017–2020 period in connection with obtaining and maintaining marketing authorizations in non-Americas jurisdictions.
PBI is subject to Irish corporation tax at the standard trading rate of 12.5%. Certain qualifying intellectual property income has been subject to the reduced 6.25% rate under Ireland's Knowledge Development box ("KDB") regime, effective from fiscal year 2016 forward. PBI's Irish tax affairs are managed in consultation with its Irish tax advisor, Thornbury & Keogh, led by Ciarán Thornbury, Lead Partner, with offices at 22 Fitzwilliam Square, Dublin 2, D02 YH68, Ireland. PBI maintains its principal banking relationship with Glenmore Bank Ireland plc and conducts independent treasury operations from its Dublin office.
III.C. Corporate Structure
The relevant corporate structure of the Penterra group for purposes of this analysis is as follows:
• Penterra Pharmaceuticals Corp. (PPC) — Delaware corporation; U.S. parent entity; publicly traded (Nasdaq: PPCA)
• Penterra Holdings Luxembourg S.à r.l. (PHL) — Luxembourg S.à r.l.; 100% owned by PPC; treated as a disregarded entity for U.S. federal income tax purposes
• Penterra Biopharma International DAC (PBI) — Irish DAC; 100% owned by PHL; IP-holding company and non-Americas principal
• Penterra Manufacturing Ireland Ltd. (PMI) — Irish private limited company; CRO Number 512347; registered at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29; contract manufacturer of oncology and immunology biologics for non-Americas markets under a cost-plus arrangement with PBI (cost plus 8%); employs approximately 620 individuals
PMI operates a modern biologics manufacturing facility in Ringaskiddy, County Cork, and produces active pharmaceutical ingredients and finished dosage forms for PBI's commercial products sold in EMEA and APAC markets. PMI's compensation under the intercompany cost-plus arrangement with PBI is determined on a cost-plus basis at a markup of 8% on total manufacturing costs, which has been separately benchmarked and is not at issue in the current examination.
III.D. The Legacy IP License Agreement
PBI holds a license from PPC to exploit certain legacy pharmaceutical compounds in territories outside the Americas. The legacy IP license agreement, which was executed contemporaneously with PBI's formation and the establishment of the CSA on July 1, 2012, covers compounds that were approved for commercial sale or were in late-stage clinical development prior to the CSA's effective date and that are not included in the intangible property subject to the cost-sharing arrangement.
The key terms of the legacy IP license agreement are as follows:
Licensed intellectual Property. The license covers all patents, patent applications, know-how, trade secrets, regulatory filings, marketing authorizations, clinical data, and related intellectual property associated with the legacy compounds identified on Schedule A to the agreement. These compounds span PPC's oncology, immunology, and rare-disease therapeutic areas and include products that had reached various stages of commercial maturity as of the license effective date.
Territory. The license grants PBI the exclusive right to commercialize the legacy compounds in all territories outside the Americas. The "Americas" is defined in the agreement as North America (the United States, Canada, and Mexico), Central America, South America, and the Caribbean. The licensed territory therefore encompasses the EMEA and APAC regions.
Exclusivity. The license is exclusive within the licensed territory. PPC retains all rights with respect to the Americas territory. PPC does not license the legacy compounds to any other entity for commercialization in the non-Americas territory.
Royalty Rate. PBI pays PPC a running royalty equal to 4.5% of net sales of the licensed legacy compounds in the non-Americas territory. "Net sales" is defined in the agreement in a manner consistent with customary pharmaceutical license practice, calculated as gross sales less trade discounts, allowances, rebates, returns, government-mandated price reductions, and value-added taxes.
Duration. The license remains in effect for the term of the underlying patents, with a provision for continuation on a royalty-bearing basis for any compound that continues to generate sales after patent expiration, subject to a step-down mechanism for post-patent-expiry sales.
Sublicensing. PBI has limited sublicensing rights subject to PPC's prior written consent, which shall not be unreasonably withheld.
Supply. PPC has no obligation to supply finished products under the legacy IP license. PBI independently manages supply through its contract manufacturing arrangement with PMI and through third-party contract manufacturers.
Improvements. Any improvements to the legacy compounds made by PPC are licensed to PBI under the same royalty terms. PBI's own improvements to legacy compounds in the non-Americas territory are retained by PBI.
The legacy IP license is separate from and supplementary to the qualified cost-sharing arrangement under which PBI co-funds ongoing research and development activities for post-2012 intellectual property. The CSA covers new molecular entities entering development after July 1, 2012, and is governed by its own terms and transfer pricing protocols. The CSA is the subject of a separate transfer pricing adjustment proposed by the IRS, which is addressed in a separate economic report and is not within the scope of this analysis.
III.E. Legacy IP Compound Revenue (Non-Americas, 2017–2020)
The table below summarizes PBI's net sales of legacy compounds in the non-Americas territory and the corresponding royalty payments to PPC at the 4.5% contractual rate for the four tax years at issue:
As reflected in the table above, legacy compound net sales in the non-Americas territory declined from $814.6 million in 2017 to $624.1 million in 2020, representing a cumulative decline of approximately 23.4% over the four-year period. This declining revenue trend is consistent with the natural product lifecycle maturation of the legacy compounds, which were originally approved or nearing approval prior to 2012 and were therefore in various stages of commercial maturity and decline during the 2017–2020 period. Factors contributing to the revenue decline include generic and biosimilar competition in certain markets, patent expirations for certain compounds, formulary and reimbursement changes, and the natural erosion of market share as newer therapies entered the market.
The declining revenue trajectory of the legacy compounds is a significant comparability factor in this analysis, as it reflects the diminishing economic value of the underlying intellectual property over time and bears directly on the appropriate royalty rate.
Total legacy IP royalties paid by PBI to PPC over the four tax years at issue amounted to approximately $130.18 million.
III.F. Key Products (Context)
While the legacy IP license is the specific transaction at issue in this report, it is helpful to provide context regarding PBI's broader commercial operations and product portfolio. PBI's principal commercial products include:
Veritaxol (oncology). Veritaxol is PPC's flagship oncology product and a blockbuster therapy for the treatment of certain solid tumors. For fiscal year 2020, Veritaxol generated global net sales of approximately $3.12 billion, of which approximately $1.34 billion (approximately 43% of global net sales) was attributable to the non-Americas territory.
Imvara (immunology). Imvara is a biologic therapy indicated for autoimmune and inflammatory conditions. For fiscal year 2020, Imvara generated global net sales of approximately $1.87 billion, of which approximately $0.79 billion (approximately 42% of global net sales) was attributable to the non-Americas territory.
Cerulon (rare disease). Cerulon is an orphan drug indicated for a rare genetic disorder. For fiscal year 2020, Cerulon generated global net sales of approximately $0.62 billion, of which approximately $0.28 billion (approximately 45% of global net sales) was attributable to the non-Americas territory.
These three products are primarily covered by the qualified cost-sharing arrangement rather than the legacy IP license. However, they provide important context for understanding PBI's overall commercial operations, the scale and sophistication of PBI's non-Americas commercialization infrastructure, and PBI's capacity to independently manage complex pharmaceutical commercial operations across a broad geographic territory.
III.G. The IRS's Proposed Adjustment to the Royalty Rate
The IRS, through its Large Business & International ("LB&I") Division, Northeast Area, Transfer Pricing Practice, has proposed increasing the royalty rate applicable to the legacy IP license from PPC's reported rate of 4.5% to a rate of 11.0% of net sales. The IRS examination is designated as LB&I-NE-TP-2022-00641, led by Revenue Agent Patricia Dunleavy, with economic analysis provided by IRS Economist Dr. Alan Washburne.
The IRS's position is based on an analysis of third-party pharmaceutical license agreements that Dr. Washburne selected as comparable uncontrolled transactions. The IRS asserts that these comparables support a royalty rate of 11.0%, reflecting what the IRS contends is the arm's-length compensation for the use of PPC's legacy intellectual property by PBI in the non-Americas territory.
The proposed additional royalty income to PPC, calculated as the difference between the IRS's proposed 11.0% rate and PPC's reported 4.5% rate applied to legacy compound net sales, is as follows:
The total proposed royalty adjustments across the four tax years amount to approximately $188,040,000 (the minor rounding difference relative to the table above reflects the IRS's rounding conventions). This royalty adjustment is part of a larger net proposed adjustment of $380.4 million, consisting of $235.01 million in CSA-related adjustments, $188.04 million in royalty adjustments, and a correlative offset of $42.65 million.
The IRS issued its Notice of Proposed Adjustment ("NOPA") on October 12, 2023, and its 30-Day Letter on November 8, 2023. PPC, through Calderwood & Harkness LLP, has protested the proposed adjustments and intends to request consideration by the IRS Office of Appeals.
IV. Legal and Regulatory Framework
IV.A. IRC § 482 — Arm's-Length Standard
Section 482 of the Internal Revenue Code provides the Commissioner of Internal Revenue with the authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances among two or more organizations, trades, or businesses owned or controlled directly or indirectly by the same interests, "if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income" of such organizations.
The implementing regulations under IRC § 482 establish the arm's-length standard as the governing principle for determining whether the results of controlled transactions are consistent with the results that would have been realized in transactions between unrelated parties dealing at arm's length under comparable circumstances. Treas. Reg. § 1.482-1(b)(1) provides that "[i]n determining the true taxable income of a controlled taxpayer, the standard to be applied in every case is that of a taxpayer dealing at arm's length with an uncontrolled taxpayer." The arm's-length standard requires that the results of a controlled transaction be consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances.
Treasury Regulation § 1.482-1(b)(2)(i) further provides that the arm's-length result must reflect the economic reality of the controlled transaction, taking into account the functions performed, risks assumed, resources employed, and the terms and conditions of the transaction. The determination of arm's-length results is inherently factual and depends upon the specific facts and circumstances of each case.
The arm's-length standard operates as a bilateral constraint: it prevents both the understatement and the overstatement of income allocable to any party to a controlled transaction. Thus, while the IRS is authorized to make adjustments to clearly reflect income, any such adjustment must itself produce a result that is consistent with what unrelated parties would have agreed to under comparable circumstances.
IV.B. Treas. Reg. § 1.482-4 — Methods for Intangible Property
Treasury Regulation § 1.482-4 sets forth the specified methods available for determining the arm's-length consideration for transfers of intangible property, including the licensing of patents, know-how, trade secrets, trademarks, and other intellectual property. The regulation prescribes several methods, including the comparable uncontrolled transaction ("CUT") method, the comparable profits method ("CPM"), the profit split method, and unspecified methods.
CUT Method — Treas. Reg. § 1.482-4(c). The CUT method determines the arm's-length royalty for a controlled transfer of intangible property by reference to the consideration charged in a comparable uncontrolled transaction. An uncontrolled transaction is considered comparable if the intangible property involved and the circumstances of the transaction are sufficiently similar to the controlled transaction that the uncontrolled transaction provides a reliable measure of an arm's-length result, or if such differences can be accounted for through reasonably reliable adjustments.
The CUT method is the most direct analogue to the comparable uncontrolled price ("CUP") method used for tangible goods and is generally considered the most reliable method for determining arm's-length royalties when sufficiently comparable uncontrolled transactions are available. The method provides a transaction-based comparison that directly tests the royalty rate itself, rather than relying on profit-level comparisons or residual calculations.
Comparable Profits Method — Treas. Reg. § 1.482-5. The CPM determines the arm's-length result by comparing the profitability of the tested party to the profitability of comparable uncontrolled entities. While the CPM can be applied to test the appropriateness of intercompany royalties indirectly (by examining whether the tested party's residual profitability after payment of the royalty is consistent with arm's-length levels), the CPM is generally considered less reliable than the CUT method for testing a specific royalty rate where comparable transactions are available.
Profit Split Method — Treas. Reg. § 1.482-6. The profit split method allocates combined operating profit from a controlled transaction between the related parties based on the relative value of each party's contributions. The profit split method is typically employed when both parties to the transaction make unique and valuable contributions that are not readily benchmarked through one-sided methods. While PBI does perform significant functions, the specific transaction at issue—a royalty rate for a license of legacy IP—is amenable to direct benchmarking through the CUT method, making the profit split method a less direct and less reliable approach in these circumstances.
IV.C. Best Method Rule — Treas. Reg. § 1.482-1(c)
Treasury Regulation § 1.482-1(c) establishes the "best method rule," which requires that the arm's-length result of a controlled transaction be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's-length result. The best method rule does not prescribe a hierarchy among the specified methods; rather, it requires a case-specific evaluation of the reliability of each method based on two primary factors:
1. Degree of comparability between the controlled transaction and the uncontrolled comparables, including the closeness of the comparables in terms of functions performed, risks assumed, contractual terms, economic conditions, and the nature of the property or services at issue; and
2. Quality of data and assumptions used in applying the method, including the completeness and accuracy of the data, the reliability of any adjustments for differences between the controlled and uncontrolled transactions, and the sensitivity of the results to deficiencies in the data.
In the context of this analysis, the CUT method is the best method for determining the arm's-length royalty rate for the PPC-PBI legacy IP license for the following reasons:
• A sufficient number of comparable uncontrolled pharmaceutical license agreements exist in the marketplace to permit a reliable application of the CUT method;
• The CUT method provides the most direct measure of the arm's-length royalty rate because it compares the tested royalty rate to royalty rates observed in comparable uncontrolled license transactions involving similar intangible property;
• The CUT method is more reliable than the CPM or the profit split method for testing a single-variable royalty rate where the specific variable at issue (the royalty rate expressed as a percentage of net sales) is directly observable in comparable transactions;
• The comparable uncontrolled agreements identified in this analysis involve pharmaceutical intellectual property in therapeutic areas consistent with PPC's legacy compound portfolio, with comparable territorial scope, product maturity, and contractual structures; and
• Any remaining differences between the comparable transactions and the controlled transaction can be assessed qualitatively and, where material, accounted for through reasonably reliable adjustments.
The selection of the CUT method as the best method is consistent with the IRS's own approach, as the IRS Economist, Dr. Washburne, also applied a CUT-based methodology in developing the IRS's proposed 11.0% rate. The dispute between the taxpayer and the IRS thus centers not on the selection of the transfer pricing method but on the identification and evaluation of the comparable uncontrolled transactions.
IV.D. Comparability Factors — Treas. Reg. § 1.482-4(c)(2)
Treasury Regulation § 1.482-4(c)(2) identifies the factors that must be considered in evaluating the comparability of uncontrolled transactions to the controlled transaction for purposes of the CUT method. These comparability factors include:
Comparability of Intangible Property. The intangible property involved in the uncontrolled transaction must be comparable to the intangible property involved in the controlled transaction. Factors relevant to this assessment include: (i) the nature of the intangible (e.g., patent, know-how, trademark, trade secret); (ii) the stage of development of the intangible (e.g., fully developed and commercialized, in clinical development, pre-clinical); (iii) the rights conveyed (e.g., exclusive vs. non-exclusive, scope of field-of-use restrictions); (iv) the profit potential or anticipated benefits from the use of the intangible; (v) the duration of the legal protection; and (vi) the uniqueness of the intangible and the availability of substitutes.
Comparability of Circumstances. The circumstances of the uncontrolled transaction must be comparable to those of the controlled transaction. Factors relevant to this assessment include: (i) the terms of the license agreement (e.g., exclusivity, territory, duration, sublicensing rights, termination provisions); (ii) the functions performed and risks assumed by the licensor and licensee; (iii) the economic conditions in the relevant markets; (iv) the product characteristics and the nature of the markets in which the products are sold; (v) the geographic scope of the license; and (vi) any other circumstances that could materially affect the price or value of the transaction.
The regulations recognize that exact comparability is rarely achievable and that differences between the controlled and uncontrolled transactions may exist. Where such differences exist, the regulations provide that adjustments may be made to account for material differences, provided that the adjustments are reasonably reliable and increase the overall reliability of the analysis.
IV.E. Arm's-Length Range — Treas. Reg. § 1.482-1(e)
Treasury Regulation § 1.482-1(e) provides guidance on the determination and application of the arm's-length range. When the application of a transfer pricing method produces a range of results from two or more comparable transactions, the arm's-length range is defined as follows:
• If the comparables are of sufficient quality and quantity, and all material differences have been identified and accounted for, the arm's-length range consists of the full range of results.
• If, however, the comparables are not of sufficient quality to permit identification and adjustment for all material differences (which is the typical case in practice), the arm's-length range is defined as the interquartile range—that is, the range from the 25th percentile to the 75th percentile of the results derived from the comparable transactions.
Under Treas. Reg. § 1.482-1(e)(2)(iii)(A), if the results of the controlled transaction fall within the arm's-length range, no allocation is warranted under IRC § 482. Conversely, if the results fall outside the arm's-length range, the Commissioner may make an adjustment to the median of the range, although the taxpayer may demonstrate that a different point within the range (or the range of the full results) is more appropriate.
In this analysis, we apply the interquartile range as the appropriate arm's-length range, consistent with the standard practice for CUT analyses in which the comparables, while reasonably comparable, may not be of sufficient quality to eliminate all potential differences.
IV.F. IRC § 6662(e) — Transfer Pricing Penalty
Section 6662(e) of the Internal Revenue Code imposes a penalty equal to 20% of the underpayment attributable to a "substantial valuation misstatement" or a "gross valuation misstatement" in connection with a transaction between related persons under IRC § 482. A substantial valuation misstatement exists if the price claimed on the return for property or services is 200% or more (or 50% or less) of the correct transfer price, or if the net § 482 transfer price adjustment exceeds the lesser of $5 million or 10% of the taxpayer's gross receipts.
Importantly, IRC § 6662(e)(3)(B) provides a reasonable-cause exception to the transfer pricing penalty. The penalty is not imposed if the taxpayer demonstrates that it had "reasonable cause" for the underpayment and acted in good faith. The regulations under IRC § 6662(e) provide that reasonable cause is established if, among other things, the taxpayer maintained contemporaneous documentation that was timely prepared and provided a reasonable basis for the transfer pricing methodology applied.
The relevance of the penalty provisions to this analysis is twofold. First, PPC maintained contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner) for each of the four tax years at issue, which documented PPC's transfer pricing methodology and supported the 4.5% royalty rate. The existence of this contemporaneous documentation provides the foundation for PPC's reasonable-cause defense under IRC § 6662(e)(3)(B). Second, the CUT analysis presented in this report provides independent, additional support for the reasonableness of PPC's 4.5% royalty rate, further reinforcing PPC's position that it had reasonable cause for reporting the 4.5% rate and acted in good faith.
IV.G. OECD Transfer Pricing Guidelines (2017, 2022 Revisions)
While the OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations do not have the force of law in the United States, they are frequently referenced as persuasive authority in U.S. transfer pricing disputes, including by the IRS, the Tax Court, and the federal appellate courts. The OECD Guidelines establish an internationally recognized framework for the application of the arm's-length standard that is broadly consistent with the principles embodied in the U.S. transfer pricing regulations.
Chapter VI of the OECD Guidelines, which addresses transfer pricing for intangibles, provides guidance on the identification and characterization of intangible property, the application of the arm's-length standard to transactions involving intangibles, and the analysis of DEMPE functions (development, enhancement, maintenance, protection, and exploitation) in connection with determining appropriate remuneration for intangible property transfers. The 2017 and 2022 revisions to Chapter VI place particular emphasis on the importance of aligning the allocation of returns from intangible property with the performance of key DEMPE functions and the assumption of economically significant risks.
The CUP/CUT methodology described in the OECD Guidelines is consistent with the approach applied in this analysis. The OECD Guidelines recognize that the CUP method (the OECD's analogue to the CUT method under U.S. regulations) is the most direct and reliable method for benchmarking royalty rates where sufficiently comparable uncontrolled transactions can be identified.
The OECD Guidelines also emphasize the importance of functional analysis in determining comparability and in assessing the appropriate allocation of returns between related parties. As discussed in Section IX of this report, PBI performs significant DEMPE functions and bears substantial risks in connection with the commercialization of the legacy compounds in the non-Americas territory. The OECD's DEMPE framework supports the conclusion that PBI's functional profile justifies a royalty rate at or near the median of the arm's-length range.
V. Methodology — Comparable Uncontrolled Transaction Analysis
V.A. Selection of CUT as the Best Method
For the reasons discussed in Section IV.C above, Whitmore has selected the CUT method under Treas. Reg. § 1.482-4(c) as the best method for evaluating the arm's-length nature of the 4.5% royalty rate charged by PPC to PBI for the intercompany license of legacy pharmaceutical intellectual property. The selection of the CUT method as the best method is predicated on the following considerations:
Availability of comparable transactions. The pharmaceutical and biopharmaceutical industries are characterized by a robust and well-documented market for intellectual property licensing transactions. Third-party license agreements involving pharmaceutical patents, know-how, and related intellectual property are commonly executed between unrelated parties, and the terms of many such agreements—including royalty rates—are publicly disclosed through SEC filings, licensing databases, and industry publications. This environment provides a sufficient population of potential comparables from which to identify transactions that are reasonably comparable to the PPC-PBI legacy IP license.
Directness of comparison. The CUT method permits a direct comparison of the tested variable—the royalty rate expressed as a percentage of net sales—against the same variable as observed in uncontrolled transactions. Unlike the CPM, which relies on profit-level comparisons and requires the identification of comparable entities (rather than comparable transactions), and unlike the profit split method, which requires the allocation of combined profits based on the relative contributions of both parties, the CUT method directly benchmarks the specific pricing variable at issue. This directness enhances the reliability of the analysis.
Consistency with the nature of the controlled transaction. The PPC-PBI legacy IP license is structured as a standard pharmaceutical running-royalty license agreement, with the royalty expressed as a fixed percentage of net sales. This structure is consistent with the structure of a large number of third-party pharmaceutical license agreements, facilitating direct comparisons. Unlike certain intercompany arrangements that involve complex, multi-component pricing structures (e.g., combined royalties, milestone payments, and equity consideration), the PPC-PBI legacy license involves a single pricing variable (the running royalty rate) that is amenable to CUT benchmarking.
Superior reliability relative to alternative methods. The CPM, while frequently applied in transfer pricing analyses, provides a less reliable measure of the arm's-length royalty rate in this case because it tests profitability at the entity level rather than the pricing of a specific transaction. The profit split method, while theoretically applicable, introduces additional complexity and subjectivity (e.g., in the determination of each party's relative contributions) that is unnecessary where directly comparable transaction-level data is available. For these reasons, the CUT method provides the most reliable measure of the arm's-length result and is therefore the best method under Treas. Reg. § 1.482-1(c).
We note that the IRS's own economic analysis, as reflected in the NOPA and the work of IRS Economist Dr. Washburne, also applied a CUT-based methodology. The IRS and the taxpayer are thus in agreement on the selection of the CUT method as the best method. The dispute between the parties relates not to the choice of method but to the identification and evaluation of comparable uncontrolled transactions and the resulting arm's-length range.
V.B. Search Strategy and Data Sources
Whitmore conducted a comprehensive search for comparable uncontrolled pharmaceutical license agreements using the following data sources:
• Pharmaceutical license agreement databases: Whitmore searched publicly available databases that compile and track pharmaceutical and biopharmaceutical licensing transactions, including databases maintained by Calderon Data Systems (Glenrock Services Inc.), Informa (Medtrack), and other industry data providers. These databases catalog license agreements by therapeutic area, geographic scope, development stage, deal structure, and financial terms.
• SEC filings: Whitmore reviewed filings with the U.S. Securities and Exchange Commission, including Forms 8-K (current reports disclosing material agreements), Forms 10-K (annual reports), and Forms 10-Q (quarterly reports), for disclosures of pharmaceutical license agreements and associated financial terms. Many publicly traded pharmaceutical companies are required to disclose the material terms of significant license agreements, including royalty rates, in their SEC filings.
• Patent and licensing registries: Whitmore reviewed patent licensing records and other publicly available intellectual property transaction records where relevant financial terms were disclosed.
• Industry publications: Whitmore reviewed pharmaceutical industry publications, trade journals, and market reports for information regarding pharmaceutical licensing transactions and royalty rate data.
The search was designed to identify the broadest possible initial universe of pharmaceutical license agreements, which was then systematically narrowed through the application of screening criteria designed to ensure comparability with the PPC-PBI legacy IP license.
Search period. The search was limited to license agreements executed between 2008 and 2020. This time frame was selected to provide temporal comparability with the PPC-PBI legacy IP license, which was executed on July 1, 2012, and was in effect throughout the 2017–2020 period at issue. Agreements executed within this window are expected to reflect market conditions, industry norms, and negotiating patterns reasonably comparable to those prevailing at the time the PPC-PBI license was negotiated and during the years at issue.
Initial search parameters. The initial search encompassed all license agreements involving pharmaceutical or biopharmaceutical intellectual property for therapeutic products, without restriction as to therapeutic area, geographic scope, development stage, or deal structure. The purpose of this broad initial search was to ensure that no potentially comparable agreements were inadvertently excluded at the outset.
V.C. Screening Criteria
The initial universe of pharmaceutical license agreements identified through the search described in Section V.B was subjected to a multi-step screening process designed to isolate transactions that are reasonably comparable to the PPC-PBI legacy IP license under the comparability standards of Treas. Reg. § 1.482-4(c)(2). The screening criteria were applied sequentially, with each step narrowing the universe of potential comparables:
Step 1 — Initial Universe. The initial search identified a total of approximately 842 third-party pharmaceutical IP license agreements from the databases, SEC filings, and other sources described above. This initial universe was intentionally broad and included agreements across all therapeutic areas, geographic scopes, development stages, and deal structures.
Step 2 — Therapeutic Area. The initial universe was narrowed to license agreements involving intellectual property in therapeutic areas that are comparable to PPC's legacy compound portfolio—specifically, oncology, immunology, and rare-disease therapeutics. Agreements involving unrelated therapeutic areas (e.g., cardiovascular, respiratory, dermatology, infectious disease, central nervous system) were excluded on the basis that differences in therapeutic area may correlate with differences in market dynamics, pricing environments, regulatory landscapes, competitive conditions, and profit potential that could materially affect royalty rates. This step reduced the universe to approximately 317 agreements.
Step 3 — Geographic Scope. The remaining agreements were screened for geographic comparability. Because the PPC-PBI legacy IP license covers non-Americas territories (EMEA and APAC), Whitmore retained only agreements with a territorial scope covering EMEA and/or APAC regions, or agreements with a multi-regional scope analogous to PBI's licensed territory. Agreements that were structured as worldwide-only licenses (where the economics of the U.S. market would dominate the royalty negotiation and inflate the observed rate) or U.S.-only licenses (which would reflect a different market environment) were excluded. This step reduced the universe to approximately 134 agreements.
Step 4 — Stage of Development. The remaining agreements were screened to include only licenses involving approved (marketed) products or compounds in late-stage clinical development (Phase III or regulatory review stage). This criterion ensures comparability with PPC's legacy compounds, which were approved for commercial sale or were nearing approval as of the date of the legacy IP license (July 1, 2012) and were fully commercialized during the 2017–2020 period at issue. Agreements involving early-stage clinical compounds (Phase I or Phase II), preclinical compounds, or platform technologies were excluded because the higher uncertainty and risk associated with earlier-stage assets would be expected to result in different royalty rate structures (e.g., lower running royalties offset by higher milestones). This step reduced the universe to approximately 68 agreements.
Step 5 — Royalty Structure. The remaining agreements were screened to include only transactions with running royalty rates expressed as a percentage of net sales, consistent with the royalty structure of the PPC-PBI legacy IP license. Agreements structured exclusively as lump-sum payments, milestone payments without running royalties, or equity-based consideration were excluded because such structures are not directly comparable to the running-royalty structure at issue. Agreements that combined running royalties with milestone payments were retained only if the running royalty component was separately identifiable and the milestones were de minimis relative to the overall economic consideration of the agreement; otherwise, they were excluded to avoid the distortive effect of bundled consideration. This step reduced the universe to approximately 38 agreements.
Step 6 — Independence. The remaining agreements were screened to confirm that the parties to each transaction were unrelated—that is, neither party held a direct or indirect ownership interest in the other, and the parties were not otherwise commonly controlled. Agreements between related parties were excluded because such transactions do not provide evidence of arm's-length pricing. Independence was confirmed through review of SEC filings, corporate registry data, and other publicly available ownership information. This step reduced the universe to approximately 27 agreements.
Step 7 — Sufficiency of Data. The remaining agreements were reviewed to confirm that the royalty rate terms were publicly available or otherwise sufficiently described to permit a reliable comparison. Agreements for which the royalty rate was not disclosed, was described only in general terms (e.g., "single-digit royalty" without a specific rate), or was subject to confidentiality restrictions that precluded identification of the specific rate were excluded. This step reduced the universe to the final set of 14 comparable uncontrolled transactions.
The application of these seven screening criteria, each of which is grounded in the comparability factors identified in Treas. Reg. § 1.482-4(c)(2), resulted in the identification of 14 comparable uncontrolled license agreements. These 14 agreements form the basis for the arm's-length range determination in this report.
V.D. Comparability Adjustments
Whitmore assessed whether adjustments to the royalty rates observed in the 14 comparable transactions were necessary or appropriate to account for material differences between the comparable transactions and the PPC-PBI legacy IP license. The following comparability factors were evaluated in connection with this assessment:
Product maturity. The legacy compounds licensed by PPC to PBI were approved for commercial sale or were in late-stage development prior to 2012 and were in various stages of commercial maturity during the 2017–2020 period. Comparables were assessed for the degree to which the licensed products were at a similar stage of commercial maturity. Products at an earlier stage of commercial life (e.g., recently approved with strong growth trajectories) might justify a higher royalty, while products at a later stage (with declining revenues) might justify a lower royalty. Where material differences in product maturity were identified, these were noted in the individual comparable analyses and considered in assessing the reliability of each comparable, but were not subject to quantitative adjustment due to the impracticability of reliably quantifying the effect of such differences on the royalty rate.
Exclusivity terms. The PPC-PBI legacy IP license is exclusive in the non-Americas territory. Comparables were assessed for the presence or absence of exclusivity provisions. All 14 retained comparables involve exclusive or co-exclusive licenses, ensuring reasonable comparability on this dimension.
Supply obligations. PPC has no supply obligation under the legacy IP license; PBI independently manages its supply chain. Comparables were assessed for the presence of supply obligations that could affect the economics of the license and, consequently, the royalty rate.
Sublicensing rights. PBI has limited sublicensing rights subject to PPC's prior consent. Comparables were assessed for the breadth of sublicensing rights, which could affect the value of the license and the associated royalty.
Minimum payment provisions. Some license agreements include minimum royalty or minimum sales commitments. The PPC-PBI legacy IP license does not contain such provisions. Comparables with material minimum payment provisions were assessed for the potential effect of such provisions on the royalty rate.
Volume/tiering provisions. Some license agreements provide for tiered royalty rates that vary with sales volume. The PPC-PBI legacy IP license specifies a flat 4.5% rate without tiering. Where comparables included tiered royalty structures, Whitmore used the effective blended royalty rate at sales volumes comparable to PBI's actual sales levels, or used the base royalty rate where the tiering provisions did not materially affect the comparability.
Regulatory risk allocation. The allocation of regulatory risk (i.e., the risk of failure to obtain or maintain marketing authorization) between the licensor and licensee can affect the royalty rate. PBI bore the regulatory risk for non-Americas marketing authorizations for the legacy compounds and incurred substantial regulatory expenditures. Comparables were assessed for the allocation of regulatory risk between the parties.
After consideration of all of the above factors, Whitmore concluded that no quantitative adjustments to the observed royalty rates were necessary or appropriate. The qualitative assessment of comparability differences was incorporated into the analysis by relying on the interquartile range (rather than the full range) as the arm's-length range, consistent with Treas. Reg. § 1.482-1(e), which contemplates the use of the interquartile range when comparables are not of sufficient quality to permit elimination of all differences through adjustments.
V.E. Statistical Methodology
The 14 royalty rates observed in the comparable uncontrolled transactions were analyzed using standard statistical methods to determine the arm's-length range. The following steps were applied:
1. The 14 royalty rates were arranged in ascending order.
2. The 25th percentile (Q1), median (Q2), and 75th percentile (Q3) were calculated using the standard interpolation method for percentile computation. The interquartile range was defined as the range from Q1 to Q3.
3. The mean and standard deviation were calculated for reference purposes but are not used to define the arm's-length range.
4. PPC's 4.5% royalty rate was compared to the interquartile range to determi